The binding sites for benztropines and dopamine in the dopamine transporter overlap

Neuropharmacology

Volumn 60, Issue 1, 2011, Pages 182-190

  Bisgaard, Heidi ^a   Larsen, M Andreas B ^a   Mazier, Sonia ^b   Beuming, Thijs ^c   Newman, Amy Hauck ^d   Weinstein, Harel ^b   Shi, Lei ^b   Loland, Claus J ^a   Gether, Ulrik ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c SCHRÖDINGER INC   (United States)

^d NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Cocaine; Dopamine transporter; Molecular modeling; Monoamine transporters; Mutagenesis; Neurotransmitter:sodium symporters

Indexed keywords

ALANINE; ASPARAGINE; BENZATROPINE; COCAINE; CYSTEINE; DOPAMINE; DOPAMINE TRANSPORTER; ISOLEUCINE; SERINE; VALINE; VESICULAR MONOAMINE TRANSPORTER;

ARTICLE; BINDING AFFINITY; BINDING ASSAY; BINDING SITE; CONTROLLED STUDY; DRUG BINDING; DRUG STRUCTURE; HUMAN; HUMAN CELL; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MOLECULAR MODEL; PREDICTION; PRIORITY JOURNAL; SEQUENCE ALIGNMENT; SITE DIRECTED MUTAGENESIS;

ANIMALS; BENZTROPINE; BINDING SITES; CERCOPITHECUS AETHIOPS; COCAINE; COS CELLS; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; MODELS, MOLECULAR; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 78149496311     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2010.08.021     Document Type: Article

References (49)

1. Agoston G.E., Wu J.H., Izenwasser S., George C., Katz J., Kline R.H., Newman A.H. Novel N-substituted 3 alpha-[bis(4'-fluorophenyl)methoxy]tropane analogues: selective ligands for the dopamine transporter. J. Med. Chem. 1997, 40:4329-4339.
2. Andersen J., Olsen L., Hansen K.B., Taboureau O., Jorgensen F.S., Jorgensen A.M., Bang-Andersen B., Egebjerg J., Stromgaard K., Kristensen A.S. Mutational mapping and modeling of the binding site for (S)-citalopram in the human serotonin transporter. J. Biol. Chem. 2009.
3. Andersen J., Taboureau O., Hansen K.B., Olsen L., Egebjerg J., Stromgaard K., Kristensen A.S. Location of the antidepressant binding site in the serotonin transporter: importance of Ser-438 in recognition of citalopram and tricyclic antidepressants. J. Biol. Chem. 2009, 284:10276-10284.
4. Andersen J., Olsen L., Hansen K.B., Taboureau O., Jorgensen F.S., Jorgensen A.M., Bang-Andersen B., Egebjerg J., Stromgaard K., Kristensen A.S. Mutational mapping and modeling of the binding site for (S)-citalopram in the human serotonin transporter. J. Biol. Chem. 2010, 285:2051-2063.
5. + symporters (NSS) aids in the use of the LeuT structure to probe NSS structure and function. Mol. Pharmacol. 2006, 70:1630-1642.
6. Beuming T., Kniazeff J., Bergmann M.L., Shi L., Gracia L., Raniszewska K., Newman A.H., Javitch J.A., Weinstein H., Gether U., Loland C.J. The binding sites for cocaine and dopamine in the dopamine transporter overlap. Nat. Neurosci. 2008, 11:780-789.
7. Chen J.G., Sachpatzidis A., Rudnick G. The third transmembrane domain of the serotonin transporter contains residues associated with substrate and cocaine binding. J. Biol. Chem. 1997, 272:28321-28327.
8. Chen N.H., Reith M.E., Quick M.W. Synaptic uptake and beyond: the sodium- and chloride-dependent neurotransmitter transporter family SLC6. Pflugers Arch. 2004, 447:519-531.
9. Chen R., Tilley M.R., Wei H., Zhou F., Zhou F.M., Ching S., Quan N., Stephens R.L., Hill E.R., Nottoli T., Han D.D., Gu H.H. Abolished cocaine reward in mice with a cocaine-insensitive dopamine transporter. Proc. Natl. Acad. Sci. U S A 2006, 103:9333-9338.
10. Deng Z., Chuaqui C., Singh J. Structural interaction fingerprint (SIFt): a novel method for analyzing three-dimensional protein-ligand binding interactions. J. Med. Chem. 2004, 47:337-344.
11. Desai R.I., Kopajtic T.A., Koffarnus M., Newman A.H., Katz J.L. Identification of a dopamine transporter ligand that blocks the stimulant effects of cocaine. J. Neurosci. 2005, 25:1889-1893.
12. Dutta A.K., Zhang S., Kolhatkar R., Reith M.E. Dopamine transporter as target for drug development of cocaine dependence medications. Eur. J. Pharmacol. 2003, 479:93-106.
13. Gainetdinov R.R., Caron M.G. Monoamine transporters: from genes to behavior. Annu. Rev. Pharmacol. Toxicol. 2003, 43:261-284.
14. Gether U., Andersen P.H., Larsson O.M., Schousboe A. Neurotransmitter transporters: molecular function of important drug targets. Trends Pharmacol. Sci. 2006, 27:375-383.
15. Goldberg N.R., Beuming T., Soyer O.S., Goldstein R.A., Weinstein H., Javitch J.A. Probing conformational changes in neurotransmitter transporters: a structural context. Eur. J. Pharmacol. 2003, 479:3-12.
16. Guptaroy B., Zhang M., Bowton E., Binda F., Shi L., Weinstein H., Galli A., Javitch J.A., Neubig R.R., Gnegy M.E. A juxtamembrane mutation in the N terminus of the dopamine transporter induces preference for an inward-facing conformation. Mol. Pharmacol. 2009, 75:514-524.
17. Henry L.K., Field J.R., Adkins E.M., Parnas M.L., Vaughan R.A., Zou M.F., Newman A.H., Blakely R.D. Tyr-95 and ile-172 in transmembrane segments 1 and 3 of human serotonin transporters interact to establish high affinity recognition of antidepressants. J. Biol. Chem. 2006, 281:2012-2023.
18. Hiranita T., Soto P.L., Newman A.H., Katz J.L. Assessment of reinforcing effects of benztropine analogs and their effects on cocaine self-administration in rats: comparisons with monoamine uptake inhibitors. J. Pharmacol. Exp. Ther. 2009, 329:677-686.
19. Huang X., Gu H.H., Zhan C.G. Mechanism for cocaine blocking the transport of dopamine: insights from molecular modeling and dynamics simulations. J. Phys. Chem. B. 2009, 113:15057-15066.
20. Iversen L. Neurotransmitter transporters and their impact on the development of psychopharmacology. Br. J. Pharmacol. 2006, 147(Suppl. 1):S82-S88.
21. Katz J.L., Libby T.A., Kopajtic T., Husbands S.M., Newman A.H. Behavioral effects of rimcazole analogues alone and in combination with cocaine. Eur. J. Pharmacol. 2003, 468:109-119.
22. Katz J.L., Kopajtic T.A., Agoston G.E., Newman A.H. Effects of N-substituted analogues of benztropine: diminished cocaine-like effects in dopamine transporter ligands. J. Pharmacol. Exp. Ther. 2004, 309:650-660.
23. Kniazeff J., Shi L., Loland C.J., Javitch J.A., Weinstein H., Gether U. A conserved intracellular ionic network regulates conformational transitions in neurotransmitter:sodium symporters. J. Biol. Chem. 2008, 283:17691-17701.
24. Koldso H., Severinsen K., Tran T.T., Celik L., Jensen H.H., Wiborg O., Schiott B., Sinning S. The two enantiomers of citalopram bind to the human serotonin transporter in reversed orientations. J. Am. Chem. Soc. 2010, 132:1311-1322.
25. Krishnamurthy H., Piscitelli C.L., Gouaux E. Unlocking the molecular secrets of sodium-coupled transporters. Nature 2009, 459:347-355.
26. Lin Z., Uhl G.R. Dopamine transporter mutants with cocaine resistance and normal dopamine uptake provide targets for cocaine antagonism. Mol. Pharmacol. 2002, 61:885-891.
27. Loland C.J., Norregaard L., Gether U. Defining proximity relationships in the tertiary structure of the dopamine transporter. Identification of a conserved glutamic acid as a third coordinate in the endogenous Zn(2+)-binding site. J. Biol. Chem. 1999, 274:36928-36934.
28. Loland C.J., Norregaard L., Litman T., Gether U. Generation of an activating Zn(2+) switch in the dopamine transporter: mutation of an intracellular tyrosine constitutively alters the conformational equilibrium of the transport cycle. Proc. Natl. Acad. Sci. U S A 2002, 99:1683-1688.
29. Loland C.J., Granas C., Javitch J.A., Gether U. Identification of intracellular residues in the dopamine transporter critical for regulation of transporter conformation and cocaine binding. J. Biol. Chem. 2004, 279:3228-3238.
30. Loland C.J., Desai R.I., Zou M.F., Cao J., Grundt P., Gerstbrein K., Sitte H.H., Newman A.H., Katz J.L., Gether U. Relationship between conformational changes in the dopamine transporter and cocaine-like subjective effects of uptake inhibitors. Mol. Pharmacol. 2008, 73:813-823.
31. Newman A.H., Katz J.L. Atypical dopamine uptake inhibitors that provide clues about cocaine's mechanism at the dopamine transporter. Transporters as Targets for Drugs 2009, S. Napier, M. Bingham (Eds.).
32. Newman A.H., Kulkarni S. Probes for the dopamine transporter: new leads toward a cocaine-abuse therapeutic - A focus on analogues of benztropine and rimcazole. Med. Res. Rev. 2002, 22:429-464.
33. Newman A.H., Allen A.C., Izenwasser S., Katz J.L. Novel 3 alpha-(diphenylmethoxy)tropane analogs: potent dopamine uptake inhibitors without cocaine-like behavioral profiles. J. Med. Chem. 1994, 37:2258-2261.
34. Raje S., Cao J., Newman A.H., Gao H., Eddington N.D. Evaluation of the blood-brain barrier transport, population pharmacokinetics, and brain distribution of benztropine analogs and cocaine using in vitro and in vivo techniques. J. Pharmacol. Exp. Ther. 2003, 307:801-808.
35. Raje S., Cornish J., Newman A.H., Cao J., Katz J.L., Eddington N.D. Pharmacodynamic assessment of the benztropine analogues AHN-1055 and AHN-2005 using intracerebral microdialysis to evaluate brain dopamine levels and pharmacokinetic/pharmacodynamic modeling. Pharm. Res. 2005, 22:603-612.
36. Sherman W., Day T., Jacobson M.P., Friesner R.A., Farid R. Novel procedure for modeling ligand/receptor induced fit effects. J. Med. Chem. 2006, 49:534-553.
37. + and substrate is triggered by substrate in a second binding site. Mol. Cell 2008, 30:667-677.
38. Singh S.K., Yamashita A., Gouaux E. Antidepressant binding site in a bacterial homologue of neurotransmitter transporters. Nature 2007, 448:952-956.
39. Singh S.K., Piscitelli C.L., Yamashita A., Gouaux E. A competitive inhibitor traps LeuT in an open-to-out conformation. Science 2008, 322:1655-1661.
40. Sinning S., Musgaard M., Jensen M., Severinsen K., Celik L., Koldso H., Meyer T., Bols M., Jensen H.H., Schiott B., Wiborg O. Binding and orientation of tricyclic antidepressants within the central substrate site of the human serotonin transporter. J. Biol. Chem. 2010, 285:8363-8374.
41. Syed S.A., Newman A.H., Othman A.A., Eddington N.D. Population pharmacokinetics, brain distribution, and pharmacodynamics of 2nd generation dopamine transporter selective benztropine analogs developed as potential substitute therapeutics for treatment of cocaine abuse. J. Pharm. Sci. 2008, 97:1993-2007.
42. Torres G.E., Amara S.G. Glutamate and monoamine transporters: new visions of form and function. Curr. Opin. Neurobiol. 2007, 17:304-312.
43. Uhl G.R., Lin Z. The top 20 dopamine transporter mutants: structure-function relationships and cocaine actions. Eur. J. Pharmacol. 2003, 479:71-82.
44. Volz T.J., Schenk J.O. A comprehensive atlas of the topography of functional groups of the dopamine transporter. Synapse 2005, 58:72-94.
45. -dependent neurotransmitter transporters. Nature 2005, 437:215-223.
46. Zhao Y., Quick M., Shi L., Mehler E.L., Weinstein H., Javitch J.A. Substrate-dependent proton antiport in neurotransmitter:sodium symporters. Nat. Chem. Biol. 2010, 6:109-116.
47. Zhou Z., Zhen J., Karpowich N.K., Goetz R.M., Law C.J., Reith M.E., Wang D.N. LeuT-desipramine structure reveals how antidepressants block neurotransmitter reuptake. Science 2007, 317:1390-1393.
48. Zhou Z., Zhen J., Karpowich N.K., Law C.J., Reith M.E., Wang D.N. Antidepressant specificity of serotonin transporter suggested by three LeuT-SSRI structures. Nat. Struct. Mol. Biol. 2009, 16:652-657.
49. Zomot E., Bendahan A., Quick M., Zhao Y., Javitch J.A., Kanner B.I. Mechanism of chloride interaction with neurotransmitter:sodium symporters. Nature 2007, 449:726-730.